VB Group Interviews This Week: Focus on Gene Sequencing, IVD, and Traditional Chinese Medicine Amid Pandemic Response

At the end of 2019, the novel coronavirus emerged abruptly and ravaged China. It can be said that this epidemic has posed a tremendous test to China and even the entire world in the fields of politics, capital, and science. AndDuring the period when people were confined to their homes by the novel coronavirus, they found themselves subjected to a relentless barrage of massive amounts of information. During this time, VCBeat curated multiple thematic series focused on nationwide epidemic prevention, aiming to provide readers with essential and objective information. Guided by our commitment to healthcare and medicine, and with the goal of offering readers as objective an industry forecast as possible, we have decided to relaunch the VB Group Interviews after a two-year hiatus, inviting industry leaders to engage in real-time online exchanges with our readers.

This week, there are three episodes of the VB Group interview series, namelyThis Wednesday (March 11) at 10:00 a.m., Bai Jingwei, Researcher and Doctoral Supervisor at Tsinghua University, Gene Sequencing Technology and Innovation；This Thursday (March 12) at 8:00 PM, Wang Haijiao, Executive Partner of GTJA Investment Group,Development and Challenges of the IVD Industry Under the Impact of the PandemicandThis Friday (March 13) at 3:30 PM, Professor Yin Hang from Tsinghua UniversityInterpreting for EveryonePerspectives on the Role of Traditional Chinese Medicine in Epidemic Prevention and Control and the Future Innovation of Modern TCM

Click the link or scan the QR code to join the group for more information,http://t.cn/AikgaMaS

Scan the QR code to join the group for more information

Keywords: Technological Innovations in Gene Sequencing; Prominent Applications During the Pandemic; Future Investment Hotspots and Areas of Focus

Time：10:00-11:00 a.m., Wednesday, March 11, 2020

Guest:Bai Jingwei, Researcher and Doctoral Supervisor at Tsinghua University

Direction:

• Overview, Development, and Innovation of Gene Sequencing Technology

• Prominent Applications of Gene Sequencing Technology in This Epidemic

• Technologies and Products Worth Investing in and Watching in This Field in the Future

Introduction:

He earned his bachelor’s degree from the College of Chemistry and Molecular Engineering at Peking University and his Ph.D. in Materials Science from the University of California, Los Angeles (UCLA), followed by postdoctoral research at IBM Thomas J. Watson Research Center. From 2013 to 2016, he was employed by Illumina Inc., a U.S.-based gene sequencing technology company, where he engaged in research and development. To date, he has published 30 papers in journals such as Nature, Nature Nanotechnology, Nano Letters, and PNAS, filed 17 U.S. invention patents, of which 8 have been granted.

Keywords: COVID-19 Testing Products; Industry Growth and Domestic SubstitutionClinical Demand and Technological Innovation – Industry Transformation

Time: 20:00-21:00, Thursday, March 12, 2020

Guest: Wang Haijiao, Executive Partner at GTJA Investment Group

Direction:

• Can COVID-19 Testing Products Achieve Routine Application in the Post-Pandemic Era?

• What is the market value and investment value of COVID-19 testing?

• What Changes Has the COVID-19 Pandemic Brought to the Industry?

• How Can SMEs Keep Pace with Clinical Needs for Technological Innovation Amid the COVID-19 Pandemic?

Introduction:

Master of Science in Biology from Fudan University, MBA; EMBA from Shanghai Advanced Institute of Finance (SAIF); Honored as “Young Investor” by the Zhongguancun Equity Investment Association in 2018. Recognized as one of “40 Under 40 Investors” by Cyzone in 2019 and named among the “Top 50 Equity Investors” by Yicai (First Financial Daily). Previously served as Assistant to the General Manager at Boyang Biotechnology Co., Ltd. and as Investment Director at Suzhou Longyue Venture Capital. Possesses over ten years of experience in entrepreneurship, corporate management, and investment within the healthcare industry, with cumulative investments exceeding RMB 6 billion.

Keywords: Traditional Chinese Medicine (TCM); Epidemic Prevention; Future of Modern TCM

Time: 15:30-16:30, Friday, March 13, 2020

Guest: Yin Hang, Professor at Tsinghua University

Introduction:

Professor Yin Hang’s research spans interdisciplinary fields, primarily focusing on chemical biology, immuno-oncology drug development, protein design, and computational simulations. Professor Yin’s team has published over 100 research papers in top-tier journals such as Science, Nature, and Proceedings of the National Academy of Sciences (PNAS), accumulating more than 6,000 total citations, with multiple studies featured as research highlights. The team has filed 11 patent applications, with four patents granted in the United States, the European Union, Japan, and other regions, and several patented technologies have been commercialized. Professor Yin has received numerous prestigious awards, including the National Science Fund for Distinguished Young Scholars from the National Natural Science Foundation of China, the David W. Robertson Award for Excellence in Medicinal Chemistry from the American Chemical Society, the Outstanding Young Professor Award from the US-China Chemistry and Chemical Biology Professors Association, and the NSF CAREER Award from the U.S. National Science Foundation.

For more exciting content,Click the link or scan the QR code to join the group and get access.http://t.cn/AikgaMaS

Scan the QR code to join the group and get more information